Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
Volume: 33, Issue: 2, Pages: 240 - 251
Published: Mar 1, 2020
Abstract
Background:
In 2015, Vyvanse (lisdexamfetamine) became the first Food and Drug Administration (FDA)-approved treatment for binge-eating disorder (BED), a condition first recognized by the DSM–V in 2013. Because pharmaceutical companies use continuing medical education (CME) to help sell drugs, we explored possible bias in CME modules on BED.Methods:
We utilized a qualitative thematic analysis research approach to identify and...Paper Details
Title
Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED)
Published Date
Mar 1, 2020
Volume
33
Issue
2
Pages
240 - 251
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History